Skip to content

Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using Two Femoral Block Techniques

Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using an Ultrasound Plus Neurostimulator Technique Versus an Approach Based on the Localization of the Femoral Artery.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02721290
Enrollment
80
Registered
2016-03-29
Start date
2016-01-31
Completion date
2020-12-31
Last updated
2019-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regional Anesthesia, Femoral Nerve Block

Keywords

Knee surgery

Brief summary

In this study, we will be comparing two approaches to the femoral block. The first or classical approach and one that is the most popular in our institution is used by combining ultrasound guidance and neurostimulator to do the block. The second is performed with the ultrasound alone aiming at the inferolateral aspect of the femoral artery with the needle and injecting. The primary endpoint of the study is the sensitive cutaneous block distribution using both techniques.

Interventions

PROCEDUREFemoral nerve block using Ultrasound and neurostimulator
PROCEDUREFemoral nerve block using Ultrasound

Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.

Sponsors

Maisonneuve-Rosemont Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for an elective surgery for which the anesthesiologist planned to do a single shot or continuous femoral nerve block.

Exclusion criteria

* Any contraindication to the femoral nerve block (coagulopathy, infection, pre-existing neuropathy, local anesthetic allergy and refusal of local anesthesia). * Refusal to participate in the study * Inability to understand or communicate the effect of local anesthesia secondary to the femoral nerve bloc.

Design outcomes

Primary

MeasureTime frameDescription
Sensitive cutaneous block distribution area for the two techniques45 minutesAfter performance of a femoral nerve block, ice will be applied on the skin to plot the anesthetized area at times 15, 30 and 45 mn. The sensation will be compared on a scale from 0 (no sensation) to 2 (no anesthesia) with the contralateral leg. An area in cm2 will be calculated for each of the patients and the two techniques will then be compared.

Secondary

MeasureTime frameDescription
Ease of ultrasound visualization of the femoral nerve45 minutesThis will be assessed by the anesthesiologist making the femoral nerve block from a scale of 1 (no visualization) to 10 (excellent visualization).
Ease of ultrasound visualization of the femoral artery45 minutesThis will be assessed by the anesthesiologist making the femoral nerve block from a scale of 1 (no visualization) to 10 (excellent visualization).
Numbers of needle redirection45 minutesThe number of time for each patients using either techniques that the needle will have been withdrawn.
Time of block completion45 minutesTime recorded from the end of the cutaneous local anesthetic injection to the end of the 20cc injection of the 0.5% Ropivacaine (time of block completion)
Paresthesia45 minutesPresence or absence of the sensation of electrical shock felt by the patient in the territory of the femoral nerve at any point while performing the block
Patient Satisfaction45 minutesSatisfaction expressed by the patient after the completion of the femoral nerve block using a scale from 1 to 4.
Vascular puncture45 minutesPresence or absence of blood return at anytime in the tubing while performing the block.

Countries

Canada

Contacts

Primary ContactIssam Tanoubi, MD
i.tanoubi@icloud.com1 844 634-3400
Backup ContactCédric Godbout-Simard, MD
cedric.godboutsimard@mail.mcgill.ca1 844 634-3400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026